568 Appendices 206. Bartolazzi A, Bellotti C, Sciacchitano S. Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Applied immunohistochemistry & molecular morphology. 2012;20:2-7. https://doi.org/10.1097/PAI.0b013e31821ee9bb. 207. Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006;48:795-800. https://doi.org/10.1111/j.1365-2559.2006.02428.x. 208. Pennelli G, Mian C, Pelizzo MR, Naccamulli D, Piotto A, Girelli ME, et al. Galectin-3 cytotest in thyroid follicular neoplasia: a prospective, monoinstitutional study. Acta cytologica. 2009;53:533-539. 209. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, et al. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology. 2005;37:296-298. https://doi. org/10.1080/00313020500169545. 210. Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head & neck. 2004;26:960-966. https://doi. org/10.1002/hed.20087. 211. Torregrossa L, Faviana P, Camacci T, Materazzi G, Berti P, Minuto M, et al. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Human pathology. 2007;38:1482-1488. https://doi.org/10.1016/j. humpath.2007.02.013. 212. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, et al. Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocrine-related cancer. 2005;12:305-317. https://doi.org/10.1677/erc.1.00944. 213. Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF. Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. Journal of the Egyptian National Cancer Institute. 2008;20:36-46. 214. Asioli S, Maletta F, Pacchioni D, Lupo R, Bussolati G. Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining. Virchows Archiv. 2010;457:43-51. https://doi.org/10.1007/s00428-010-0910-z. 215. Raggio E, Camandona M, Solerio D, Martino P, Franchello A, Orlandi F, et al. The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. Journal of endocrinological investigation. 2010;33:378-381. https://doi.org/10.3275/6444. 216. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342. https://doi.org/10.1038/modpathol.3880312. 217. Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. European journal of endocrinology. 2011;165:447-453. https://doi.org/10.1530/eje-11-0181. 218. Lacoste-Collin L, d’Aure D, Berard E, Rouquette I, Delisle MB, Courtade-Saidi M. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls. Cytopathology. 2014;25:160-169. https://doi.org/10.1111/cyt.12128. 219. Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer. 2005;105:87-95. https://doi. org/10.1002/cncr.21026. 220. Khurana KK, Truong LD, LiVolsi VA, Baloch ZW. Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Archives of pathology & laboratory medicine. 2003;127:579-583. https://doi.org/10.1043/0003-9985(2003)127<0579:ciicbp>2.0.co;2. 221. Baloch ZW, Abraham S, Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Human pathology. 1999;30:1166-1171. 222. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedenius J. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid. 2003;13:371-380. https://doi.org/10.1089/105072503321669866. 223. Pisani T, Pantellini F, Centanni M, Vecchione A, Giovagnoli MR. Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas. Anticancer research. 2003;23:3323-3326. 224. Addati T, Achille G, Centrone M, Petroni S, Popescu O, Russo S, et al. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study. Cytopathology. 2015. https://doi.org/10.1111/cyt.12196. 225. Coban I, Cakir A, Unal TD, Bassullu N, Karpuz V, Dogusoy GB, et al. Emerin expression in well differentiated epithelial lesions of thyroid: implications in papillary thyroid carcinoma diagnosis and predicting malignant behavior. Pathol Oncol Res. 2015;21:357-366. https://doi.org/10.1007/s12253-014-9828-0. 226. Chandan VS, Faquin WC, Wilbur DC, Khurana KK. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Cancer. 2006;108:331-336. https://doi.org/10.1002/ cncr.22172.
RkJQdWJsaXNoZXIy MTk4NDMw